The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

2.0 Checking for updates and scope: after consultation (to be completed by the Developer and submitted with the revised scope)

<table>
<thead>
<tr>
<th>2.1 Have any potential equality issues been identified during consultation, and, if so, what are they?</th>
</tr>
</thead>
<tbody>
<tr>
<td>It was noted that people with cognitive impairment, learning difficulties, those whose first language is not English, people with sensory impairment, people who are homeless or in secure settings, and people with a current or past history of substance use disorder need to be considered in development of this guideline.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2.2 Have any changes to the scope been made as a result of consultation to highlight potential equality issues?</th>
</tr>
</thead>
<tbody>
<tr>
<td>As a result of the comments, the consideration of people with a current or past history of substance use disorder has been removed from the scope as a group requiring consideration and instead included in the equalities impact assessment form, to clarify that specific management for this group isn’t within the scope of the guideline, but consideration will be made when undertaking reviews and drafting recommendations.</td>
</tr>
</tbody>
</table>
2.3 Is the primary focus of the guideline a population with a specific disability-related communication need?

If so, do the key messages for the public need to be produced in an alternative version?

If so, which alternative version is recommended?

The alternative versions available are:

- large font or audio versions for a population with sight loss
- British Sign Language videos for a population deaf from birth
- ‘Easy read’ versions for people with learning disabilities or cognitive impairment.

Does an alternative version(s) of the consultation documents also need to be produced?

No.

Updated by Developer: Serena Carville, Guideline Lead

Date: 20/12/17

Approved by NICE quality assurance lead: Kay Nolan, Guideline Lead

Date: 02/02/18